Are working memory and glutamate concentrations involved in early-life stress and severity of psychosis?

Running Title: Early-life stress and psychosis severity

Authors: Mark Corcoran[a], Emma L. Hawkins[b], Denis O'Hora[a], Heather C. Whalley[b], Jeremy Hall[c], Stephen M. Lawrie[b], Maria R. Dauvermann[a,d,e*]

Institutional Affiliations:

[a] School of Psychology, National University of Ireland Galway, Galway, Ireland

[b] Division of Psychiatry, University of Edinburgh, Edinburgh, UK

[c] Neuroscience and Mental Health Research Institute, Cardiff University School of Medicine, Cardiff, UK

[d] McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, USA

[e] Department of Psychiatry, University of Cambridge, Cambridge, UK

*Corresponding author:

Dr Maria Dauvermann, PhD

Postdoctoral Researcher

School of Psychology

National University of Ireland Galway

maria.dauvermann@nuigalway.ie

Tel: +353 91495953

Number of Figures: 1

Number of Tables: 5

Abstract

Objective: Occurrences of early-life stress (ELS) are associated with the severity of psychotic symptoms and working memory (WM) deficits in patients with psychosis (PSY). This study investigated potential mediation roles of WM behavioural performance and Glutamate concentrations in prefrontal brain regions on the association between ELS and psychotic symptom severity in PSY.

Method: Forty-seven patients with PSY (established schizophrenia, $n = 30$; bipolar disorder, $n = 17$) completed measures of psychotic symptom severity. In addition, data on ELS and WM performance was collected in both patients with PSY and healthy controls (HC; $n = 41$). Resting-state Glutamate concentrations in the bilateral dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) were also assessed with Proton Magnetic Resonance Spectroscopy for both PSY and HC groups. *T*-tests, analyses of variance and regression analyses were utilised.

Results: Participants with PSY reported significantly more ELS occurrences and showed poorer WM performance than HC. Furthermore, individuals with PSY displayed lower Glutamate concentrations in the left DLPFC than HC. Neither ELS nor WM performance were predictive of severity of psychotic symptoms in participants with PSY. However, we found a significant negative correlation between Glutamate concentrations in the left DLPFC and ELS occurrence in HC only.

Conclusion: In individuals with PSY, the current study found no evidence that the association between ELS and psychotic symptoms is mediated by WM performance or prefrontal Glutamate concentrations. In HC, the association between ELS experience and Glutamate concentrations may indicate a neurometabolite effect of ELS that is independent of an illness effect in psychosis.

Keywords: Psychosis, Early-life stress, Working memory, Glutamate, Left Dorsolateral Prefrontal Cortex

Significant Outcomes	
	Our findings of reduced Glutamate concentrations in the left dorsolateral prefrontal cortex and poorer working memory performance in patients with psychosis (including both schizophrenia and bipolar disorder) provide evidence for illness-related changes.
	The significant relationship between early-life stress experience and Glutamate concentrations in the left dorsolateral prefrontal cortex in healthy controls indicate preliminary evidence for general neurobiological effect of ELS.
Limitations	
	The early-life stress measure used in this study does not directly ask participants about abusive and neglectful experiences during childhood

	although it is known that such experiences are highly prevalent in individuals with a psychotic disorder. This may account for the lack of a relationship between early-life stress occurrences and psychotic symptom severity in our findings. However, it is also known that other environmental risk factors are implicated in the onset and severity of psychosis. Due to the relatively small sample, our analyses were not sensitive to weaker associations among early-life stress occurrences, working memory performance, Glutamate concentrations and psychotic symptom severity.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

1) Introduction

Psychotic disorders are debilitating conditions that are primarily characterised by positive symptoms (including delusions, hallucinations, and disorganized thoughts, negative symptoms (such as avolition, alogia or apathy) and cognitive deficits (such as social cognition and working memory impairments). The latter can occur prior to the diagnosis of a psychotic disorder and can worsen with illness progression [1,2]. Cognitive deficits are widely considered to be core symptoms of schizophrenia (SZ) [3] and bipolar disorder (BD) [4,5] and are also associated with reductions in working memory performance. Working memory deficits are one of the main neurocognitive impairments found in subjects with first-episode psychosis [6,7] and in patients at the established stage [8]. Deficits in working memory are important given the role of working memory in information retention and manipulation in order to perform abilities, such as speech and multi-tasking [9] and involve the recruitment of the dorsolateral prefrontal cortex (DLPFC) [10–12]. Furthermore, working memory deficits are associated with impaired daily functioning in patients with a psychotic disorder [13].

Epidemiological and clinical studies have also consistently reported the impact of stress-related environmental risk factors on the severity of psychotic symptoms in patients with SZ and BD, such as early-life stress (ELS) which includes physical abuse, physical neglect, emotional abuse, emotional neglect, sexual abuse and household dysfunction [14–25] among cannabis use [26] and urbanicity [27,28]. In addition, recent evidence suggests that the occurrence of ELS also impacts on neurocognitive function, such as working memory performance in both individuals with PSY and HC [29–31] as well as brain activation and connectivity in HC [32,33]. However, little is known about the underlying mechanism between the environmental risk factor of ELS and working memory function in individuals with PSY.

The Glutamate Hypothesis of Schizophrenia [34] and the *N*-methyl-D-aspartate receptor (NMDA-R) hypofunction model [35] posit that aberrant Glutamate systems [36] may be implicated in the pathophysiology of schizophrenia and psychosis. Proton Magnetic Resonance Spectroscopy (^{1}H-MRS) studies examined both the Glutamate Hypothesis of Schizophrenia and the NMDA-r hypofunction model by measuring resting-state Glutamate levels in prefrontal brain regions in individuals with SZ and BP. Such studies reported inconsistent findings of Glutamate levels in the dorsolateral prefrontal cortex (DLPFC) in patients with SZ [37] with studies reporting (i) increased Glutamate levels [38,39], (ii) decreased Glutamate levels [40] or (iii) no difference in Glutamate levels [41] in the DLPFC compared to healthy controls (HC). For Glutamate levels in the ACC in patients with SZ, there are further inconsistent findings with the majority of studies demonstrating no difference in concentrations of Glutamate or Glutamate-related metabolites, such as Glutamine or Glutamate and Glutamine combined (Glx) concentrations between chronic patients with SZ and HC [42–46]. However, a small number of studies also reported decreased concentrations of Glutamate between patients with SZ and HC [47–49]. The

pattern of findings in patients with BD differs from patients with SZ, where individuals with BD consistently showed higher Glx levels in the DLPFC and ACC when compared to HC [50,51]. Focusing on working memory deficits, it has been proposed that altered Glutamate regulation is one of the main neurobiological pathways underlying working memory impairments in psychosis based on both preclinical and clinical evidence [52–54]. Further support for the role of Glutamate during working memory in individuals with PSY comes from a recent study using functional ^{1}H-MRS [55].

In the last few years, emerging evidence proposes a role of stress, in particular social stress, in aberrant glutamatergic transmission in the PFC in rodents [56,57], which has also been in shown in HC who have experienced ELS [58]. Importantly, it has been shown that stress, in particular chronic social stress, resulted in both deficits in working memory and glutamatergic dysregulation in the PFC in rodents [59–61]. However, to date no study has examined the association between ELS experience and severity of psychotic symptoms in individuals with PSY when considering Glutamate concentrations as a potential neurobiological mechanism, including working memory function [62,63].

1.1) Aims of the study

In this study, we investigated whether there is a relationship between the experience of ELS and severity of psychotic symptoms in PSY. In addition, we examined whether working memory performance and Glutamate concentrations during resting-state in the bilateral DLPFC and the ACC as measured with ^{1}H-MRS mediate this relationship between the ELS experience and severity of psychotic symptoms.

2) Material and Methods

2.1) Participants

Forty-seven participants with psychosis (SZ = 30, BD = 17) and 41 HC were recruited for the study. PSY and HC were recruited from the Royal Edinburgh Hospital, associated hospitals and the Scottish Mental Health Research Register (http://www.smhrn.org.uk/). Diagnosis of SZ and BD was based on interview using the Structured Clinical Interview for DSM-IV (First et al., 2002). Inclusion criteria included (i) diagnosis of established SZ or BD, and (ii) no acute psychotic symptoms at the time of the scan. Exclusion criteria included (i) history of any major psychiatric illness other than SZ or BD, (ii) history of severe brain injury, (iii) history of a neurological disorder, and (iv) dependency or harmful use of alcohol or drugs during the last 12 months. Also, HC were excluded if they had a family history of SZ or BD. All participants provided written informed consent. The study was approved by the local Research Ethics Committee (09/MRE00/81).

2.2) Measures

2.2.1) Demographic Measures

Participants provided information regarding their age, sex and education status. Participants were also asked regarding medication use (antipsychotic medication, mood stabilisers, antidepressant medication). Smoking status has not been recorded.

2.2.2) Clinical Measures

The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) is a 30-item standardised clinical interview to rate the presence and severity of positive and negative symptoms in PSY. The measure consists of the following scales: Positive symptoms, negative symptoms, general symptoms and total score. Items were re-scored to 0 ("Absent") to 6 ("Extreme") for symptoms during the past week with higher scores indicating greater severity. Internal reliability for the three subscales of positive symptoms, negative symptoms and general symptoms has been reported as adequate (Chronbach alpha's .73 to .83) [64]. Previous studies have indicated adequate validity of the PANSS [64]. Symptom rating took place within one week of the ^{1}H-MRS acquisition.

2.2.3) Environmental Questionnaires

The Childhood Life Events Questionnaire (CLEQ; http://bdrn.org/) is a 13-item verbally administered measure of ELS shared by the Bipolar Disorder Research Network (BDRN [65]). All participants were asked if they had experienced any or all of a list of 12 adverse events prior to the age of 16 years as previously reported [66,67]. This list includes death of a parent, death of a sibling, death of a friend, parental separation, parental divorce, admission to hospital, hospitalisation of parent, visible deformity, teenage pregnancy or fatherhood, imprisoned parent and suspension from school. Responses ranged from 0

("No") to 1 ("Yes"). While no questions regarding childhood abuse or neglect were asked, participants were given the opportunity to provide this information by the final item which is an open-ended question: "*Are there any other significant life events you experienced as a child that are not mentioned above?*"

2.3) Working Memory Data

All participants performed the verbal "2-Back" task. They were presented with a sequence of single capital letters. The experimental block design consisted of (i) the baseline or "0-Back" condition; (ii) the "1-Back" condition; and (iii) the "2-Back" condition. Full experimental details are presented in the Supplementary Material.

2.4) Brain Acquisition and Analysis

2.4.1) Structural MRI acquisition and analysis

Brain scans were collected using a 3 T Siemens Verio (Erlangen, Germany) MRI scanner using a manufacturer-supplied 12-element matrix head coil at the Clinical Research Imaging Centre (CRIC), the Queen's Medical Research Institute, Edinburgh, UK. After a sagittal localizer, T1-weighted magnetization-prepared rapid-acquisition gradient echo (MPRAGE) MR images were obtained using TR=2300 ms, TE = 2.98 ms, and TI=900 ms, (Flip angle = 9, FOV = 256mm x 256 mm) with an isotropic voxel resolution of 1 mm, parallel to AC-PC plane.

2.4.2) Proton Magnetic Resonance Spectroscopy Data Acquisition and Analysis

2.4.2.1) Magnetic Resonance Spectroscopy data acquisition

We acquired MRS point-resolved selective spectroscopy (PRESS) spectra with voxel placements in the ACC, right and left DLPFC. The voxels were shimmed using the Siemens advance mode. We acquired a water unsuppressed spectra with 16 averages and a water suppressed spectra with 128 averages. The TE was set to 80ms and the TR was set to 3000ms. The phase cycling was set to the Siemens 16 EXOR-cycle mode and the bandwidth was 2500Hz with over-sampling enabled. The voxels in the DLPFC measure 20 x 20 x 20 mm (8 cm^3) and in the ACC measures 30 x 20 x 15 mm (9 cm^3).

This followed a standardized protocol, with navigation steps to determine the coronal slice for placement. Cortical feature identification was used to designate the voxel centre, followed by rotations of the voxel in the transverse and sagittal views to obtain the final placement. The location of the ACC voxel is shown in Figure 1A and the placement of the left DLPFC voxel is shown in Figure 1B. Details for the voxel placement are presented in the Supplemental Material and in a previous paper [68]. An example of a spectrum acquired in the dACC in a HC (Figure 1C).

INSERT Figure 1

2.4.2.2) Metabolite measurement

Spectral metabolite quantification was performed in LCModel version 6.2 (http://www.s-provencher.com/pages/lcmodel.shtml) using a gamma_press_te80_123mhz basis set provided at http://s-provencher-com for use with the Siemens 3T Verio scanner. LCModel obtains maximum-likelihood estimates of metabolite concentrations and their uncertainties (Cramer-Rao lower bounds; CRLB). The quality of the spectra obtained and the specificity of the measurement of a given metabolite were evaluated using the CRLB measure of uncertainty. This is a measure of the specificity of the peak in the spectrum associated with a given metabolite. Only metabolite measurements that were associated with a fitting error (CRLB) of <15% were included in the analysis.

The raw spectra were read into the graphical user interface for LCModel and processed through LC Model with eddy current correction enabled and internal water reference was used to give the metabolite in institutional units. For each voxel the metabolite values derived from LCModel were corrected for voxel cerebrospinal fluid (CSF) content as per the equation:

$$Met_{CI} = Met_I * (1 / 1 - F_{CSF}) \qquad\qquad [1]$$

Where Met_{CI} is the metabolite in institutional units and corrected for partial volume effects, Met_I is the internal water scaled metabolite value given by LC model and F_{CSF} is the fractional CSF occupancy of the voxel. The fractional CSF volume was determined from the segmentation of the T_1-weighted scan and the voxel placement and rotation noted at scan time. The T1-weighted images were segmented into grey matter, white matter and CSF maps using SPM8 (Statistical Parametric Mapping; http://fil.ion.ucl.ac.uk/spm/). The CSF volume in each voxel was extracted using a c-script that sampled the SPM segmentation maps at the native space location noted for each voxel at time of scan.

2.5)   Statistical Analysis

2.5.1)   Demographic Data

Frequencies, means and standard deviations were calculated for sex, age and level of education in Statistical Package for Social Sciences Version 25 (SPSS) [69]. Smoking status was not recorded.

2.5.2)   Clinical and Environmental Data

A series of *t*-tests were conducted to examine differences between groups on measures, such as PANSS total scores, PANSS positive symptoms, PANSS negative symptoms, PANSS general scores, ELS data and Glutamate concentrations (separately in the right DLPFC, left DLPFC and ACC). In following analyses, a multivariate ANOVA (MANOVA) was conducted to examine group differences in Glutamate concentrations in the bilateral DLPFC and ACC. Multiple linear regressions assessed

whether ELS occurrences, WM performance or Glutamate metabolite concentrations (separately in the bilateral DLPFC and ACC) predicted psychotic symptom severity by introducing these predictors systematically across blocks. Statistical significance was set at a *p* value below .05. Pearson product-moment correlations were computed to examine the relationships between ELS occurrence, WM behavioural performance, Glutamate metabolite concentrations and psychotic symptom severity. *P* values were adjusted for multiple comparison using the Hochberg method in R Studio [70].

2.5.3) Working memory data

Behavioural performance was calculated using the sensitivity index (*d'*) (Eq. [1])[71]. Behavioural performance on the 0-Back, 1-Back and 2-Back conditions between the groups was compared in SPSS using independent t-tests and ANOVAs.

d' = z (Hits) – z (False Alarms)
z = statistical Z value   [2]

2.5.4) Glutamate concentrations

Analysis of covariance (ANCOVA) was preformed to examine the hypothesised differences in Glutamate concentrations in each region between the PSY and HC groups. Age and sex were entered in as covariates for all comparisons.

3) Results

3.1) Demographic, clinical and working memory data

Demographic and clinical data are presented in Table 1. Ages ranged from 18 to 67 years ($M = 39.5$, $SD = 12.99$) with an average of 90 months of illness duration. Most participants (55%) completed post-secondary education. The majority of participants who took part in the study were male (66.3%). Demographic and clinical data for SZ and BD subgroups are presented in the Supplemental Materials (STable 1).

INSERT TABLE 1

3.1.1) Clinical data

3.1.1.1) Psychotic symptom severity

PANSS severity in PSY were assessed with comparable severity (Table 1). In addition, independent *t*-tests revealed a significant subgroup difference in PANSS positive symptoms ($t_{(45)} = 2.36$, $p = .046$, $d = 0.76$), with the SZ group scoring higher than the BD group. There were no significant group differences in PANSS total scores ($t_{(45)} = 0.945$, $p = .220$, $d = 0.29$), PANSS negative symptoms ($t_{(45)} = 1.26$, $p = .160$, $d = 0.42$), or PANSS general symptoms ($t_{(45)} = -0.38$, $p = .543$, $d = 0.66$; STable1).

3.1.2) Early-life stress

The following reported experiencing no (n; HC = 15; PSY = 8), one (HC = 11; PSY = 6), two (HC = 8; PSY = 6), three (HC = 2; PSY = 10), or four or more (HC = 3, PSY = 11) occurrences of ELS. Regarding childhood trauma (i.e., abuse and/or neglect), 2.4% of HC reported such experiences, compared to 12.2% of PSY participants (SZ = 13.3%, BD = 11.7%). An independent *t*-test (PSY vs. HC) revealed a significant group difference in ELS scores ($t_{(78)} = 3.29$, $p = .001$, $d = 0.74$) with PSY reporting greater occurrence ($M = 2.49$, $SD = 1.90$) than HC ($M = 1.23$, $SD = 1.48$). A one-way ANOVA (SZ vs. BD vs. HC) revealed a significant subgroup difference in ELS scores ($F_{(2, 79)} = 6.729$, $p = .002$, $\eta^2 = 0.149$). Post-hoc analyses revealed a significant group difference between the HC and the SZ groups ($p = .001$) in ELS scores, with the SZ group scoring higher (see Stable 1). There was no significant group difference between the BD and HC groups ($p = .267$) and the BD and SZ groups ($p = .272$) on ELS scores.

3.1.3) Working memory performance

To examine group differences in behavioural performance on the N-Back task, a series of *t*-tests were conducted (HC vs. PSY). There was no significant difference on the 0-Back performance ($t_{(74)} = 1.622$, $p = .109$, $d = .372$). For both the 1-Back and 2-Back conditions, PSY performed less accurately than HC. Regarding 1-Back performance, there was a significant group difference ($t_{(74)} = 3.212$, $p = .002$, d

= .734), with the PSY group (M = -0.60, SD = 1.87) scoring lower than the HC group (M = 0.57, SD = 1.26). Regarding 2-Back performance, a significant group difference was also observed ($t_{(74)}$ = 2.60, p = .011, d = .594) with the PSY group (M = -0.47, SD = 1.70) performing worse than the HC group (M = 0.45, SD = 1.38).

To examine any differences in N-Back performance between subgroups, a series of one-way ANOVAs (HC vs. SZ vs. BD). Regarding behavioural performance on the 0-Back task, we did not find any significant differences between the three groups ($F_{(2,76)}$ = 1.31, p = .277, η2 = .035). Regarding the 1-Back task, a significant difference was observed ($F_{(2,76)}$ = 5.121, p = .008, η2 = .123). Post-hoc analyses revealed that the SZ group performed significantly poorer (p = .012) than the HC group. There was no significant difference between the SZ and BD groups (p = .970) or the BD and HC groups (p = .092). On the 2-Back task, a significant group difference was also found ($F_{(2,76)}$ = 3.357, p = .040, η2 = .084). Post-hoc analyses revealed that the SZ group scored significantly lower (p = .049) than the HC group. There were no significant differences between the SZ and BD group (p = .961) or between the BD and HC group (p = .228).

3.2)   Glutamate concentrations

The number of participants who met the criterion of data quality are presented in Table 2. A series of one-way ANCOVAs (PSY vs. HC) were conducted to examine whether Glutamate concentrations in the three brain areas varied according to group, while controlling for age and sex. The results of the testing found a significant difference in Glutamate concentration in the left DLPFC between groups ($F_{(1, 63)}$ = 5.742, p = .020, partial η^2 = 0.084), with the PSY group reporting lower concentrations of Glutamate than the HC group (see Table 2). There were no significant differences between the PSY and HC groups with regards to Glutamate concentration in the right DLPFC (p = .324) or ACC (p = .971). Extension of the inclusion criteria (Glutamate standard deviation < 30%) resulted in no significant difference in Glutamate concentrations in the bilateral DLPFC or ACC between the PSY and HC groups (p > .05). These analyses were repeated for subgroups (SZ vs. BD vs. HC). No significant difference was found for the right or left DLPFC or ACC (see Supplemental Material).

INSERT TABLE 2

3.3)   Correlational analyses

Pearson's bivariate correlations were used to identify associations between severity of clinical symptoms, ELS occurrences, Glutamate concentrations (right DLPFC, left DLPFC and ACC) and WM performance in a series of analyses. Firstly, severity of clinical symptoms and occurrence of ELS in PSY only was tested (Table 3). Secondly, correlations between ELS and Glutamate concentrations in

both HC and PSY were run separately of each of the three brain regions (right DLPFC, left DLPFC and ACC) (Table 4). Finally, relationships between ELS experience and WM performance were examined for both groups (Table 5). *P* values were adjusted for multiple comparisons using the Hochberg method. The alpha level was set at .05.

INSERT TABLE 3

INSERT TABLE 4

INSERT TABLE 5

There were no significant correlations between the occurrence of ELS and severity of psychotic symptoms in the PSY group (all $p > .05$; Table 3). Regarding Glutamate levels, a significant negative correlation between the occurrence of ELS and Glutamate concentration in the left DLPFC ($r = -.449$, $p = .029$; Table 4) was observed in the HC group only. In the PSY group, there were no significant correlations between the occurrence of ELS and concentrations of Glutamate in the right DLPFC, left DLPFC or ACC (all $p > .05$). We also did not observe any significant correlations between the occurrence of ELS and working memory performance in the HC or PSY group (all $p > .05$; Table 5).

3.4)   Predictors of severity of psychotic symptoms

For the PSY group, occurrences of ELS, working memory performance and Glutamate concentrations were systematically added across blocks in four multiple linear regressions predicting severity of psychotic symptoms (PANSS total score, PANSS positive symptoms, PANSS negative symptoms and PANSS general score). This process was repeated for Glutamate concentrations in each of the three brain regions (right DLPFC, left DLPFC and ACC). No model was predictive of psychotic symptoms (all $p > .05$).

In addition, we repeated these analyses to predict the relationship between ELS, working memory and psychotic symptoms for the BD and SZ groups separately. No model significantly predicted symptoms in the SZ group (all $p > .05$). In patients with BD, however, the model that included 2-Back working memory performance ($\beta = -.722$) significantly predicted negative symptoms ($F_{(1,7)} = 6.531$, $p = .043$), explaining 44% of the variance of negative symptom severity scores. The same model (working memory $\beta = -.718$), significantly predicted PANSS general scores ($F_{(1,7)} = 6.370$, $p = .045$), explaining 43% of the variance. No other model was predictive of psychotic symptoms (all $p > .05$).

9

3.5)   Multivariate analyses for psychotic symptom severity differences between clinical group and early-life stress occurrences

To examine differences in psychotic symptom severity between both clinical groups (SZ and BD) and ELS experience, reported ELS experience was dichotomised into absent levels (e.g. individuals who reported no ELS experience; SZ = 4, BD = 4) and present levels (e.g. individuals who reported at least one event of ELS, SZ = 20, BD = 13). A 2 x 2 design (SZ vs. BD and Absent ELS vs. Present ELS) MANOVA revealed no interaction effect between the clinical groups and the occurrence of ELS (Wilks' λ = .911, $F_{(4, 30)}$ = 1.145, p = .344, partial $\eta 2$ = 0.089). While a significant main effect for clinical group was found (Wilks' λ = .794, $F_{(3, 35)}$ = 3.021, p = .043, partial $\eta 2$ = 0.206), there was no significant group difference in severity of clinical symptoms for PANSS total scores, PANSS positive symptoms, PANSS negative symptoms or PANSS general symptoms (all p > .05). There was also no main effect found for ELS experience (Absent vs. Present levels) (Wilks' λ = .970, $F_{(3, 35)}$ = 0.355, p = .786, partial $\eta 2$ = 0.030).

4) Discussion

The main aims of this study were to examine the association between the occurrence of ELS and severity of psychotic symptoms in PSY. Furthermore, we studied whether Glutamate concentrations in prefrontal brain regions would mediate this relationship between ELS experience and psychotic symptom severity.

One of the main findings was that patients with PSY experienced significantly higher occurrences of ELS than HC, which is consistent with previous research [17,72]. This finding of greater prevalence of occurrences of ELS in PSY compared to the general population is at the basis of gaining a better understanding of the aetiology of psychotic symptoms following the experience of ELS [73–75]. The elucidation of this potential relationship has significant clinical and research implications for improving treatment avenues, such as pharmacological treatment (based on altered Glutamate concentrations) or Cognitive Remediation Trainings (based on altered working memory function). In our additional analyses focusing on both SZ and BP, we found that SZ reported higher ELS exposure when compared to HC, whereas BD showed comparable levels to HC. This latter finding contrasts previous meta-analyses, which suggested that ELS occurrences was significantly higher amongst BD compared to HC [71,76]. A possible reason for this discrepancy is the choice of ELS measure of the CLEQ in this study when compared to the Childhood Trauma Questionnaire (CTQ) among others [54].

Contrary to our hypothesis, the occurrence of ELS was not significantly associated with the severity of psychotic symptoms in patients with PSY. This contrasts previous studies in which positive correlations between these two measures were revealed [51,63,64]. One reason for this discrepancy could be the choice of ELS measure of the CLEQ this study. Unlike commonly used measures of childhood trauma or early-life adversity, such as the CTQ [54] or the Adverse Childhood Experiences [77], the CLEQ does not directly ask participants if they have experienced abuse (e.g., physical abuse) or neglect (e.g., emotional neglect) but provides an open-ended question for such experiences to be reported (“*Are there are any other significant life events you experienced as a child that are not mentioned above?*”). This open question may have resulted in an under-reporting of abusive and neglectful experiences in this study. Support for this interpretation comes from a previous meta-analysis which reported that, dependent on adversity type, between 26% and 39% of participants with PSY reported experiencing trauma as a child [78]. However, this figure was just 12.2% for individuals with PSY in this study. Despite the established association between childhood trauma and severity of psychotic symptoms [14–25,72,79], it is also known that other environmental risk factors, such as cannabis use, migration and urbanicity are highly correlated with psychosis [26,28,66]. Recently, it has been suggested that several measurements for the assessment of ELS should be used to cover different aspects of ELS [30].

11

In the current study, ELS experiences were not significantly associated with working memory performance despite finding that individuals with PSY had significantly increased ELS experience and reduced working memory performance relative to HC. These group differences for both the low and high difficulty levels during working memory are consistent with meta-analyses and systematic reviews repeatedly confirming this [80–82]. We speculate that the lack of a significant relationship between ELS and working memory in our study may be due to the working memory data utilised. In other words, it is possible that a neurobiological measure of working memory function in the form of blood oxygenated level-dependent (BOLD) response of brain activity as measured with functional Magnetic Resonance Imaging (fMRI) may be required to reveal a potential mediation role of reduced working memory function on the relationship between ELS and severity of psychotic symptoms. Support for this interpretation comes from inconsistently reported relationships between ELS experience and working memory function across studies [29–31] when behavioural performance is considered. In contrast, widely established findings of altered BOLD responses of the DLPFC in individuals with PSY when compared to HC during working memory [12,83] emphasise the greater reliability to study the role of working memory on the severity of symptoms, while the laterality of the DLPFC underlying working memory function seems to be variable across studies. In addition, a recent study linking Glutamate concentrations as well as Glutamate + Glutamine (Glx) levels during a working memory task adds further support to the potential relevance of using brain function during working memory in individuals with psychosis [55]. Emerging evidence for utilising brain activation data during working memory to study this association between ELS exposure and working memory also emphasises the recruitment of brain activation of the DLPFC in HC with the experience of childhood trauma [32,33,84,85] and rodents following chronic stress exposure [59–61].

Focusing on the ^{1}H-MRS data, individuals with PSY demonstrated significantly reduced Glutamate concentrations in the left DLPFC compared to HC. Previous research on differences in glutamatergic neurotransmission (e.g. Glutamate, Glx and Gln concentrations) in BD, SZ and HC has produced mixed findings. Studies have reported increased Glx concentrations in the left DLPFC in BD relative to HC [86–89], but significant differences in Glx between individuals with SZ (regardless of medication status) and HC have not been observed [90]. Meta-analytical research has reported inconsistent findings between studies regarding Glutamate concentrations in the DLPFC (both right and left) in patients with SZ and HC. Furthermore, there were no significant differences in Glutamate concentration in the right DLPFC or ACC in individuals with PSY compared to HC. Findings from previous studies in these areas are also inconsistent [37,91,92]. However, a number of studies have found no evidence of group differences in Glutamate, Glutamine or Glx concentrations between chronic medicated patients with SZ and HC [42–46]. A limitation of the previous research is that many studies interpret Glutamate, Gln and Glx concentrations interchangeably, so BD- and SZ-related increases[47,93], that are specific to one of these

indicators (e.g., Gln or Glx) but not others may complicate the picture. Further research is required to better understand the roles of each of the Glutamate-related metabolites in the DLPFC and ACC in PSY. Finally, our novel findings of this study is that ELS occurrences were inversely associated with Glutamate concentrations in the left DLPFC for the HC group only. Previous studies on HC focused on the effect of acute stress on the PFC, with reports of both elevated Glx concentrations [94] and no change in Glutamate levels [95]. To our knowledge, this is the first study providing preliminary evidence of a link between ELS exposure and altered Glutamate concentrations in the DLPFC in humans, which is supporting impairments of glutamatergic neurotransmission previously reported in rodents after chronic social stress [62,63]. However, we did not observe a significant relationship between ELS experience and Glutamate concentrations in individuals with PSY. This observed association in HC only is comparable to a stronger relationship between the experience of ELS and deficits in neurocognitive function (including working memory) in HC than in individuals with PSY [30,33,96]. It has been suggested that such a finding could be due to the fact that the effect of ELS cannot be isolated from other known implicated factors on cognitive function and severity of psychotic symptoms in PSY, such as genetic risk factors, current and acute stress levels [97], medication effects [30,31]. However, given the strong link between ELS and increased likelihood of developing PSY and the support of aberrant glutamatergic transmission in the DLPFC in PSY is it also possible that the lack of significant findings in individuals with PSY was limited by methodological shortcomings, including sample size.

Future research studying relationships between ELS, cognitive function and neurobiological markers in PSY and other stress-sensitive psychiatric disorders should focus on overcoming limitations of a variety of neurocognitive batteries and ELS measures [30,31] that are challenging to interpret. Emerging evidence on combining ELS, cognitive, endocrine, cytokine and neuroimaging data will lead to greater insight into the interrelationships and therefore aetiology of PSY.

References

1.   MacDonald AW, Schulz SC. What We Know: Findings That Every Theory of Schizophrenia Should Explain. *Schizophr Bull*. 2009;35(3):493-508. doi:10.1093/schbul/sbp017

2.   Fusar-Poli P, Howes OD, Allen P, et al. Abnormal Frontostriatal Interactions in People With Prodromal Signs of Psychosis. *Arch Gen Psychiatry*. 2010;67(7):683. doi:10.1001/archgenpsychiatry.2010.77

3.   Gold JM. Cognitive deficits as treatment targets in schizophrenia. *Schizophr Res*. 2004;72(1):21-28. doi:10.1016/j.schres.2004.09.008

4.   Martinez-Aran A, Vieta E. Cognition as a target in schizophrenia, bipolar disorder and depression. *Eur Neuropsychopharmacol*. 2015;25(2):151-157. doi:10.1016/j.euroneuro.2015.01.007

5.   Bortolato B, Miskowiak KW, Köhler CA, Vieta E, Carvalho AF. Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. *Neuropsychiatr Dis Treat*. 2015;11:3111-3125. doi:10.2147/NDT.S76700

6.   Seidman LJ. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium<subtitle>Relationship to Family History and Conversion to Psychosis</subtitle><alt-title>Neuropsychology of Prodrome to Psychosis</alt-title>. *Arch Gen Psychiatry*. 2010;67(6):578. doi:10.1001/archgenpsychiatry.2010.66

7.   Kim HS, Shin NY, Jang JH, et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. *Schizophr Res*. 2011;130(1-3):170-175. doi:10.1016/j.schres.2011.04.023

8.   Genevsky A, Garrett CT, Alexander PP, Vinogradov S. Cognitive training in schizophrenia: a neuroscience-based approach. *Dialogues Clin Neurosci*. 2010;12(3):416-421. http://www.ncbi.nlm.nih.gov/pubmed/20954435%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3181983.

9.   Vöhringer PA, Barroilhet SA, Amerio A, et al. Cognitive Impairment in Bipolar Disorder and Schizophrenia: A Systematic Review. *Front Psychiatry*. 2013;4. doi:10.3389/fpsyt.2013.00087

10.   Roberts BM, Libby LA, Inhoff MC, Ranganath C. Brain activity related to working memory for temporal order and object information. *Behav Brain Res*. 2018;354:55-63. doi:10.1016/j.bbr.2017.05.068

11.   Jalbrzikowski M, Murty VP, Stan PL, et al. Differentiating between clinical and behavioral phenotypes in first-episode psychosis during maintenance of visuospatial working memory. *Schizophr Res*. 2018;197:357-364. doi:10.1016/j.schres.2017.11.012

12.   Glahn DC, Ragland JD, Abramoff A, et al. Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. *Hum Brain Mapp*. 2005;25(1):60-69. doi:10.1002/hbm.20138

13. Vesterager L, Christensen TT, Olsen BB, et al. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia. *Schizophr Res*. 2012;141(2-3):251-256. doi:10.1016/j.schres.2012.08.023

14. Day R, Nielsen JA, Korten A, et al. Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization. *Cult Med Psychiatry*. 1987;11(2):123-205. doi:10.1007/BF00122563

15. Lataster J, Myin-Germeys I, Lieb R, Wittchen H-U, van Os J. Adversity and psychosis: a 10-year prospective study investigating synergism between early and recent adversity in psychosis. *Acta Psychiatr Scand*. 2012;125(5):388-399. doi:10.1111/j.1600-0447.2011.01805.x

16. Shannon C, Douse K, McCusker C, Feeney L, Barrett S, Mulholland C. The association between childhood trauma and memory functioning in schizophrenia. *Schizophr Bull*. 2011;37(3):531-537. doi:10.1093/schbul/sbp096

17. Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective-and cross-sectional cohort studies. *Schizophr Bull*. 2012;38(4):661-671. doi:10.1093/schbul/sbs050

18. Mayo D, Corey S, Kelly LH, et al. The Role of Trauma and Stressful Life Events among Individuals at Clinical High Risk for Psychosis: A Review. *Front Psychiatry*. 2017;8. doi:10.3389/fpsyt.2017.00055

19. Holtzman CW, Trotman HD, Goulding SM, et al. Stress and neurodevelopmental processes in the emergence of psychosis. *Neuroscience*. 2013;249:172-191. doi:10.1016/j.neuroscience.2012.12.017

20. Bechdolf A, Thompson A, Nelson B, et al. Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. *Acta Psychiatr Scand*. 2010;121(5):377-384. doi:10.1111/j.1600-0447.2010.01542.x

21. Gershon A, Johnson SL, Miller I. Chronic stressors and trauma: prospective influences on the course of bipolar disorder. *Psychol Med*. 2013;43(12):2583-2592. doi:10.1017/S0033291713000147

22. Thompson JL, Kelly M, Kimhy D, et al. Childhood trauma and prodromal symptoms among individuals at clinical high risk for psychosis. *Schizophr Res*. 2009;108(1-3):176-181. doi:10.1016/j.schres.2008.12.005

23. van Os J, Kenis G, Rutten BPF. The environment and schizophrenia. *Nature*. 2010;468(7321):203-212. doi:10.1038/nature09563

24. Walder DJ, Faraone S V., Glatt SJ, Tsuang MT, Seidman LJ. Genetic liability, prenatal health, stress and family environment: Risk factors in the Harvard Adolescent Family High Risk for Schizophrenia Study. *Schizophr Res*. 2014;157(1-3):142-148.

doi:10.1016/j.schres.2014.04.015

25. Üçok A, Kaya H, Uğurpala C, et al. History of childhood physical trauma is related to cognitive decline in individuals with ultra-high risk for psychosis. *Schizophr Res*. 2015;169(1-3):199-203. doi:10.1016/j.schres.2015.08.038

26. Murray RM, Englund A, Abi-Dargham A, et al. Cannabis-associated psychosis: Neural substrate and clinical impact. *Neuropharmacology*. 2017;124:89-104. doi:10.1016/j.neuropharm.2017.06.018

27. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med*. 2004;2(1):13. doi:10.1186/1741-7015-2-13

28. Newbury J, Arseneault L, Caspi A, Moffitt TE, Odgers CL, Fisher HL. Cumulative Effects of Neighborhood Social Adversity and Personal Crime Victimization on Adolescent Psychotic Experiences. *Schizophr Bull*. 2018;44(2):348-358. doi:10.1093/schbul/sbx060

29. Goodman JB, Freeman EE, Chalmers KA. The relationship between early life stress and working memory in adulthood: A systematic review and meta-analysis. *Memory*. 2019;27(6):868-880. doi:10.1080/09658211.2018.1561897

30. Vargas T, Lam PH, Azis M, Osborne KJ, Lieberman A, Mittal VA. Childhood trauma and neurocognition in adults with psychotic disorders: A systematic review and meta-analysis. *Schizophr Bull*. 2019;45(6):1195-1208. doi:10.1093/schbul/sby150

31. Dauvermann MR, Donohoe G. The role of childhood trauma in cognitive performance in schizophrenia and bipolar disorder – A systematic review. *Schizophr Res Cogn*. 2019;16:1-11. doi:10.1016/j.scog.2018.11.001

32. Philip NS, Sweet LH, Tyrka AR, et al. Early life stress is associated with greater default network deactivation during working memory in healthy controls: a preliminary report. *Brain Imaging Behav*. 2013;7(2):204-212. doi:10.1007/s11682-012-9216-x

33. Philip NS, Sweet LH, Tyrka AR, et al. Exposure to childhood trauma is associated with altered n-back activation and performance in healthy adults: implications for a commonly used working memory task. *Brain Imaging Behav*. 2016;10(1):124-135. doi:10.1007/s11682-015-9373-9

34. Coyle JT. NMDA Receptor and Schizophrenia: A Brief History. *Schizophr Bull*. 2012;38(5):920-926. doi:10.1093/schbul/sbs076

35. Coyle JT. The Glutamatergic Dysfunction Hypothesis for Schizophrenia. *Harv Rev Psychiatry*. 1996;3(5):241-253. doi:10.3109/10673229609017192

36. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry*. 1994;51(3):199-214.

http://www.ncbi.nlm.nih.gov/pubmed/8122957. Accessed December 11, 2018.

37. Poels EMP, Kegeles LS, Kantrowitz JT, et al. Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. *Schizophr Res*. 2014;152(2-3):325-332. doi:10.1016/J.SCHRES.2013.12.013

38. Rüsch N, Tebartz van Elst L, Valerius G, et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. *Schizophr Res*. 2008;99(1-3):155-163. doi:10.1016/j.schres.2007.05.024

39. Olbrich HM, Valerius G, Rüsch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. *World J Biol Psychiatry*. 2008;9(1):59-63. doi:10.1080/15622970701227811

40. Ćurčić-Blake B, Bais L, Sibeijn-Kuiper A, et al. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A 1H MRS study. *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2017;78:132-139. doi:10.1016/J.PNPBP.2017.05.020

41. Yoo SY, Yeon S, Choi CH, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. *Schizophr Res*. 2009;111(1-3):86-93. doi:10.1016/j.schres.2009.03.036

42. Kraguljac N V, Reid MA, White DM, den Hollander J, Lahti AC. Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. *Neuropsychopharmacology*. 2012;37(12):2635-2642. doi:10.1038/npp.2012.126

43. Rowland LM, Kontson K, West J, et al. In Vivo Measurements of Glutamate, GABA, and NAAG in Schizophrenia. *Schizophr Bull*. 2013;39(5):1096-1104. doi:10.1093/schbul/sbs092

44. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: A proton spectroscopic imaging study at 4 tesla. *Biol Psychiatry*. 2011;69(1):19-27. doi:10.1016/j.biopsych.2010.08.024

45. Shirayama Y, Obata T, Matsuzawa D, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study. *Neuroimage*. 2010;49(3):2783-2790. doi:10.1016/j.neuroimage.2009.10.031

46. Reid MA, Stoeckel LE, White DM, et al. Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia. *Biol Psychiatry*. 2010;68(7):625-633. doi:10.1016/j.biopsych.2010.04.013

47. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and Glutamine in the Anterior Cingulate and Thalamus of Medicated Patients With Chronic Schizophrenia and Healthy Comparison Subjects Measured With 4.0-T Proton MRS. *Am J Psychiatry*. 2003;160(12):2231-2233. doi:10.1176/appi.ajp.160.12.2231

48. Théberge J, Al-Semaan Y, Jensen JE, et al. Comparative study of proton and phosphorus

magnetic resonance spectroscopy in schizophrenia at 4 Tesla. *Psychiatry Res Neuroimaging*. 2004;132(1):33-39. doi:10.1016/j.pscychresns.2004.08.001

49. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). *Schizophr Res*. 2009;108(1-3):69-77. doi:10.1016/j.schres.2008.11.014

50. Soeiro-de-Souza MG, Pastorello BF, Leite C da C, Henning A, Moreno RA, Garcia Otaduy MC. Dorsal Anterior Cingulate Lactate and Glutathione Levels in Euthymic Bipolar I Disorder: 1H-MRS Study. *Int J Neuropsychopharmacol*. 2016;19(8). doi:10.1093/ijnp/pyw032

51. Öngür D, Jensen JE, Prescot AP, et al. Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania. *Biol Psychiatry*. 2008;64(8):718-726. doi:10.1016/j.biopsych.2008.05.014

52. Javitt DC. Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine-Glutamate Interactions. In: *International Review of Neurobiology*. Vol 78. ; 2007:69-108. doi:10.1016/S0074-7742(06)78003-5

53. Dauvermann MR, Whalley HC, Schmidt A, et al. Computational neuropsychiatry - Schizophrenia as a cognitive brain network disorder. *Front Psychiatry*. 2014;5(MAR). doi:10.3389/fpsyt.2014.00030

54. Dauvermann MR, Lee G, Dawson N. Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. *Br J Pharmacol*. 2017;174(19):3136-3160. doi:10.1111/bph.13919

55. Jelen LA, King S, Horne CM, Lythgoe DJ, Young AH, Stone JM. Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task. *Eur Neuropsychopharmacol*. 2019;29(2):222-234. doi:10.1016/j.euroneuro.2018.12.005

56. Zhang L, Hernández VS, Vázquez-Juárez E, Chay FK, Barrio RA. Thirst Is Associated with Suppression of Habenula Output and Active Stress Coping: Is there a Role for a Non-canonical Vasopressin-Glutamate Pathway? *Front Neural Circuits*. 2016;10. doi:10.3389/fncir.2016.00013

57. Schiavone S, Morgese MG, Bove M, et al. Ketamine administration induces early and persistent neurochemical imbalance and altered NADPH oxidase in mice. *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2020;96:109750. doi:10.1016/j.pnpbp.2019.109750

58. Duncan NW, Hayes DJ, Wiebking C, et al. Negative childhood experiences alter a prefrontal-insular-motor cortical network in healthy adults: A preliminary multimodal rsfMRI-fMRI-MRS-dMRI study. *Hum Brain Mapp*. 2015;36(11):4622-4637. doi:10.1002/hbm.22941

59. Yuen EY, Liu W, Karatsoreos IN, et al. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. *Mol Psychiatry*. 2011;16(2):156-170.

doi:10.1038/mp.2010.50

60. Shao Y, Yan G, Xuan Y, et al. Chronic social isolation decreases glutamate and glutamine levels and induces oxidative stress in the rat hippocampus. *Behav Brain Res*. 2015;282:201-208. doi:10.1016/j.bbr.2015.01.005

61. Onaolapo AY, Ayeni OJ, Ogundeji MO, Ajao A, Onaolapo OJ, Owolabi AR. Subchronic ketamine alters behaviour, metabolic indices and brain morphology in adolescent rats: Involvement of oxidative stress, glutamate toxicity and caspase-3-mediated apoptosis. *J Chem Neuroanat*. 2019;96:22-33. doi:10.1016/j.jchemneu.2018.12.002

62. Aas M, Navari S, Gibbs A, et al. Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis? *Schizophr Res*. 2012;137(1-3):73-79. doi:10.1016/j.schres.2012.01.035

63. Janssen I, Krabbendam L, Bak M, et al. Childhood abuse as a risk factor for psychotic experiences. *Acta Psychiatr Scand*. 2004;109(1):38-45. http://www.ncbi.nlm.nih.gov/pubmed/14674957. Accessed February 21, 2019.

64. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261

65. Upthegrove R, Chard C, Jones L, et al. Adverse childhood events and psychosis in bipolar affective disorder. *Br J Psychiatry*. 2015;206(3):191-197. doi:10.1192/bjp.bp.114.152611

66. Neilson E, Bois C, Gibson J, et al. Effects of environmental risks and polygenic loading for schizophrenia on cortical thickness. *Schizophr Res*. 2017;184:128-136. doi:10.1016/j.schres.2016.12.011

67. Barker V, Bois C, Neilson E, et al. Childhood adversity and hippocampal and amygdala volumes in a population at familial high risk of schizophrenia. *Schizophr Res*. 2016;175(1-3):42-47. doi:10.1016/j.schres.2016.04.028

68. Thomson PA, Duff B, Blackwood DHR, et al. Balanced translocation linked to psychiatric disorder, glutamate, and cortical structure/function. *npj Schizophr*. 2016;2:16024. doi:10.1038/npjschz.2016.24

69. IBM. Statistical Package for the Social Sciences. 2017.

70. RStudio Team. RStudio: Integrated development environment for R (Version 0.99.486). 2018. http://www.rstudio.com/.

71. Macmillan NA, Creelman CD, Creelman CD. Detection Theory : A User's Guide. September 2004. doi:10.4324/9781410611147

72. Bailey T, Alvarez-Jimenez M, Garcia-Sanchez AM, Hulbert C, Barlow E, Bendall S. Childhood trauma is associated with severity of hallucinations and delusions in psychotic disorders: A systematic review and meta-analysis. *Schizophr Bull*. 2018;44(5):sbx161-sbx161. doi:10.1093/schbul/sbx161

73. Chase KA, Melbourne JK, Rosen C, et al. Traumagenics: At the intersect of childhood trauma, immunity and psychosis. *Psychiatry Res*. 2019;273:369-377. doi:10.1016/j.psychres.2018.12.097

74. Read J, Fosse R, Moskowitz A, Perry B. The traumagenic neurodevelopmental model of psychosis revisited. *Neuropsychiatry (London)*. 2014;4(1):65-79. doi:10.2217/npy.13.89

75. Barker V, Gumley A, Schwannauer M, Lawrie SM. An integrated biopsychosocial model of childhood maltreatment and psychosis. *Br J Psychiatry*. 2015;206(03):177-180. doi:10.1192/bjp.bp.113.143578

76. Etain B, Mathieu F, Henry C, et al. Preferential association between childhood emotional abuse and bipolar disorder. *J Trauma Stress*. 2010:n/a-n/a. doi:10.1002/jts.20532

77. The ACE Score. The ACE Study Website. http://www.acestudy.org/ace_score. Published 2003.

78. Bonoldi I, Simeone E, Rocchetti M, et al. Prevalence of self-reported childhood abuse in psychosis: A meta-analysis of retrospective studies. *Psychiatry Res*. 2013;210(1):8-15. doi:10.1016/j.psychres.2013.05.003

79. Agnew-Blais J, Danese A. Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: A systematic review and meta-analysis. *The Lancet Psychiatry*. 2016;3(4):342-349. doi:10.1016/S2215-0366(15)00544-1

80. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: A meta-analysis. *Psychol Med*. 2009;39(6):889-905. doi:10.1017/S0033291708004558

81. Frydecka D, Eissa AM, Hewedi DH, et al. Impairments of working memory in schizophrenia and bipolar disorder: The effect of history of psychotic symptoms and different aspects of cognitive task demands. *Front Behav Neurosci*. 2014;8(NOV). doi:10.3389/fnbeh.2014.00416

82. Hamilton LS, Altshuler LL, Townsend J, et al. Alterations in functional activation in euthymic bipolar disorder and schizophrenia during a working memory task. *Hum Brain Mapp*. 2009;30(12):3958-3969. doi:10.1002/hbm.20820

83. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: A meta-analysis of normative functional neuroimaging studies. *Hum Brain Mapp*. 2005;25(1):46-59. doi:10.1002/hbm.20131

84. Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. *Nat Rev Neurosci*. 2016;17(10):652-666. doi:10.1038/nrn.2016.111

85. Teicher MH, Samson JA. Annual Research Review: Enduring neurobiological effects of childhood abuse and neglect. *J Child Psychol Psychiatry*. 2016;57(3):241-266. doi:10.1111/jcpp.12507.Annual

86. Michael N, Erfurth A, Ohrmann P, et al. Acute mania is accompanied by elevated

glutamate/glutamine levels within the left dorsolateral prefrontal cortex. *Psychopharmacology (Berl)*. 2003;168(3):344-346. doi:10.1007/s00213-003-1440-z

87.   Michael N, Erfurth A, Pfleiderer B. Elevated metabolites within dorsolateral prefrontal cortex in rapid cycling bipolar disorder. *Psychiatry Res Neuroimaging*. 2009;172(1):78-81. doi:10.1016/j.pscychresns.2009.01.002

88.   Frey BN, Stanley JA, Nery FG, et al. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo [1] H MRS study. *Bipolar Disord*. 2007;9(s1):119-127. doi:10.1111/j.1399-5618.2007.00454.x

89.   Taylor MJ. Could glutamate spectroscopy differentiate bipolar depression from unipolar? *J Affect Disord*. 2014;167:80-84. doi:10.1016/j.jad.2014.05.019

90.   Kaminski J, Gleich T, Fukuda Y, et al. Association of Cortical Glutamate and Working Memory Activation in Patients With Schizophrenia: A Multimodal Proton Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study. *Biol Psychiatry*. 2020;87(3):225-233. doi:10.1016/j.biopsych.2019.07.011

91.   Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia a meta-analysis of proton magnetic resonance spectroscopy studies. *JAMA Psychiatry*. 2016;73(7):665-674. doi:10.1001/jamapsychiatry.2016.0442

92.   Marsman A, Van Den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: A focused review and meta-analysis of1H-MRS studies. *Schizophr Bull*. 2013;39(1):120-129. doi:10.1093/schbul/sbr069

93.   Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. *Bipolar Disord*. 2012;14(5):478-487. doi:10.1111/j.1399-5618.2012.01033.x

94.   Zwanzger P, Zavorotnyy M, Gencheva E, et al. Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide-a 3T-MRS study in healthy subjects. *Neuropsychopharmacology*. 2013;38(9):1648-1654. doi:10.1038/npp.2013.61

95.   Houtepen LC, Schür RR, Wijnen JP, et al. Acute stress effects on GABA and glutamate levels in the prefrontal cortex: A 7T 1H magnetic resonance spectroscopy study. *NeuroImage Clin*. 2017;14:195-200. doi:10.1016/j.nicl.2017.01.001

96.   Malarbi S, Abu-Rayya HM, Muscara F, Stargatt R. Neuropsychological functioning of childhood trauma and post-traumatic stress disorder: A meta-analysis. *Neurosci Biobehav Rev*. 2017;72:68-86. doi:10.1016/j.neubiorev.2016.11.004

97.   Dauvermann MR, Donohoe G. Cortisol stress response in psychosis from the high-risk to the chronic stage: a systematic review. *Ir J Psychol Med*. 2019;36(4):305-315. doi:10.1017/ipm.2019.27

Table 1. Demographic and clinical details

	HC	PSY	Test	*p*
N	41	47		
Age Mean (SD)	38.29 (14.44)	40.62 (11.63)	t	.406
Sex (M:F)	23:18	33:14	χ^2	.170
Education (1:2:3) [†]	10:2:24	8:7:24	χ^2	.112
PANSS Total [b] Mean (SD)	-	23.28 (17.87)	-	-
PANSS Positive [‡] Mean (SD)	-	5.30 (5.00)	-	-
PANSS Negative [‡] Mean (SD)	-	6.38 (7.11)	-	-
PANSS General [‡] Mean (SD)	-	11.60 (8.60)	-	-
CLEQ [§] Mean (SD)	1.23 (1.48)	2.49 (1.90)	t	.001*

CLEQ, Childhood Life Events Questionnaire; HC, Healthy Controls; PANSS, Positive and Negative Symptom Scale.

[†] 0, Compulsory; 1, More than compulsory; 2, Post-Secondary

[‡] Rescaled total PANSS scores

[§] Rescaled CLEQ scores

* *p* < .001

Table 2. Glutamate concentrations in institutional units (IU) [‡]

	HC	PSY	Test	*p*
R DLPFC	8.64 (2.11) *n* = 33	8.04 (1.46) *n* = 29	*F*	.324
L DLPFC	8.20 (1.36) *n* = 34	7.41 (1.37) *n* = 33	*F*	.020*
ACC	7.79 (1.71) *n* = 28	7.17 (1.87) *n* =35	*F*	.971

ACC, Anterior Cingulate Cortex; HC, Healthy Controls; L DLPFC, Left Dorsolateral Prefrontal Cortex; PSY, individuals with psychosis; R DLPFC, Right Dorsolateral Prefrontal Cortex.

* $p < .05$

[†] Participants with Glutamate concentration standard deviation exceeding 15% were excluded from this table.

[‡] Age and sex were entered as covariates

Table 3. Pearson correlation coefficients for severity of clinical symptoms and occurrence of early-life stress for individuals with psychosis

	PSY	
N	41	
	CLEQ Scale	
	r	*p*
PANSS Scale		
Total	.009	.996
Positive Symptoms	.011	.996
Negative Symptoms	.052	.996
General Symptoms	-.030	.996

PANSS, Positive and Negative Symptom Scale; PSY, Individuals with psychosis

Table 4. Pearson correlation coefficients for Glutamate concentrations and occurrence of early-life stress for healthy controls and individuals with psychosis

Brain Region		HC	PSY
R DLPFC	r	-.088	-.045
	p	.703	.827
	n	30	26
L DLPFC	r	-.449	.163
	p	.029*	.577
	n	31	31
ACC	r	.131	.306
	p	.514	.089
	n	27	32

ACC, Anterior Cingulate Cortex; HC, healthy controls; PSY individuals with psychosis; L DLPFC, Left Dorsolateral Prefrontal Cortex; R DLPFC, Right Dorsolateral Prefrontal Cortex

Table 5. Pearson correlation coefficients for behavioural performance during working memory and occurrence of early-life stress for healthy controls and individuals with psychosis

	HC		PSY	
N	37		32	
N-Back	*r*	*p*	*r*	*p*
0-Back	-.343	.114	.025	.891
1-Back	-.050	.888	-.052	.888
2-Back	-.052	.921	.122	.921

HC, Healthy Controls; PSY; Individuals with psychosis

Figure 1.